Author: Ashraf, Talha ; Azam Rana, Burhan E ; Bin Majeed, Muhammad Bilal ; Riaz, Amjad ; Imran, Muhammad ; Yaseen, Muhammad ; Bilal, Muhammad ; Ashraf, Muhammad Kamran ; Husnain, Ali ; Mushtaq, Muhammad Hassan

We hypothesized that human chorionic gonadotropic (hCG) could replace LH in the maturation media for buffalo oocytes, and hCG administration before ovum pick-up (OPU) enhances in-vitro development of buffalo oocytes. Objectives were 1) to investigate the effect of hCG supplementation on nuclear maturation, oocyte development, and granulosa cell mRNA abundance of genes related to growth and antioxidant pathways and 2) to determine the effect of hCG administration before OPU on in-vitro oocyte development. In Experiment 1, buffalo oocytes retrieved from slaughterhouse ovaries were maturated in the media supplemented with 0.5 μg of LH or 2 IU of hCG. After fertilization, cleavage and embryo were assessed on 48 h and 7 d of the culture, respectively. The nuclear maturation of the oocytes and granulosa cells mRNA abundance of genes (AREG,EREG,NRG1,CYP19A1,GDF9,CASP9,SOD1) were assessed after maturation. In Experiment 2, buffaloes were synchronized and superstimulated with FSH and 6 h before OPU, randomly assigned to either receive saline (CON, n = 4) or 1500 IU of hCG (hCG, n = 6). Four OPU sessions per buffalo were conducted at weekly intervals and retrieved oocytes were maturated and fertilized in-vitro. In Experiment 1, nuclear maturation, cleavage, embryo production, and mRNA abundance of the genes related to growth and steroidogenesis did not differ between treatments but SOD1 gene expression tended (P = 0.10) to lower in hCG treatment as compared with LH. In Experiment 2, oocytes retrieved from hCG-treated buffaloes resulted in a higher proportion of cleavage (84.0 vs. 42.5 ± 8.9 %, P = 0.02) and embryo (84.0 vs 24.0 ± 7.3, P < 0.01) than CON. In conclusion, hCG supplementation in the maturation media yielded comparable outcomes to that of LH, and hCG administration 6 h before OPU enhanced the in-vitro developmental competency of the buffalo oocytes.

01 Feb 2025·Clinical Endocrinology

Efficacy of Gonadotropin Treatment for Induction of Spermatogenesis in Men With Pathologic Gonadotropin Deficiency: A Meta‐Analysis

Review

Author: Muir, Christopher A. ; Zhang, Ting ; Conway, Ann J. ; Jayadev, Veena ; Handelsman, David J.

ABSTRACTIntroductionHypogonadotropic hypogonadism (HH) is a treatable cause of nonobstructive azoospermic male infertility. Gonadotropin treatment can successfully induce spermatogenesis in most patients, although comprehensive quantitative summary data on spermatogenic outcomes like those required to induce pregnancy is lacking in the literature.Materials and MethodsSystematic review and meta‐analysis of outcomes related to male reproductive function following gonadotropin treatment.ResultsOur search strategy identified 41 studies encompassing 1673 patients with a mean age of 25 (± 5) years. Average sperm concentration achieved after a median of 18 months of gonadotropin treatment was 11.6 M/mL of ejaculate (95% CI 8.4–14.9). Sperm concentrations > 0, > 1, > 5, > 10 and > 20 M/mL were achieved by 78%, 55%, 36%, 24% and 15% of patients, respectively. Mean sperm output and the proportion of patients achieving all sperm thresholds were significantly greater following combined hCG/FSH treatment compared with hCG monotherapy. When compared by diagnosis, patients with congenital HH (CHH) had significantly lower mean sperm output compared with patients with hypopituitarism or mixed patient cohorts that did not differentiate between CHH and hypopituitarism. Treatment‐related increases in testosterone and testicular volume (TV) were not different between hCG and combined hCG/FSH treated patients, although increases in TV were lower in men with CHH compared with those with hypopituitarism.ConclusionsGonadotropin treatment successfully induced spermatogenesis in most men with pathological gonadotropin deficiency. Sperm outputs more consistent with those typically needed to induce a natural pregnancy were less commonly achieved. Despite similar effects on serum testosterone and TV, combined hCG/FSH appeared more efficacious than hCG alone at inducing spermatogenesis.

01 Feb 2025·Animal Reproduction Science

Hormonal induction and seasonal variation in male reproductive viability of the Southern Rocky Mountain boreal toad

Article

Author: Langhorne, Cecilia J ; Jacobs, Leah ; Upton, Rose ; Della Togna, Gina ; Calatayud, Natalie E ; Mullen, Amanda C

The Southern Rocky Mountain boreal toad (Anaxyrus boreas boreas) depends on both the rearing of wild-collected egg masses and a long-standing conservation breeding program (CBP), the latter of which heavily relies on assisted reproductive technologies (ARTs) to support wild populations. Achieving consistent reproductive success in the CBP, however, remains a significant challenge. Natural breeding has not led to a sustained increase in reproductive capacity, prompting the exploration of exogenous hormone treatments as an alternative strategy. This study specifically examined male responses to the administration of human chorionic gonadotropin (hCG), a previously tested hormone, in combination with gonadotropin-releasing hormone agonist (GnRH-A), either individually or together, to evaluate their effects on sperm induction and viability across different seasons. Insights into how hormone treatments and seasonality influence sperm acquisition can guide managers in improving breeding outcomes within ex situ populations by enhancing their understanding of reproductive health, applying hormone treatments at the optimal time of year, and determining the best timing for high quality sperm collection. These advancements can increase reproductive capacity and support long-term genetic management through biobanking. Results indicated that combining hCG and GnRH-A yielded the highest sperm quantity and quality, although further optimization of hormone dosages could improve outcomes. Seasonal factors significantly influenced hormonal efficacy, with variations in sperm concentration and quality observed across months.

News (Medical) associated with Human Chorionic Gonadotrophin (Mochida Pharmaceutical Co., Ltd.)

23 Jan 2023

·www.businesswire.com

Therapeutic Solutions International Spin-Off Campbell Neurosciences Provides Progress Update in Quest for Addressing Suicide as a Medical Condition

ELK CITY, Idaho--( BUSINESS WIRE )--Therapeutic Solutions International (TSOI) announced today an update on progress made by its subsidiary Campbell Neurosciences, Inc. Campbell was founded on the principle that suicide in numerous situations is a result of biological factors that can be diagnosed and addressed using medical approaches. In contrast to other fields of medicine, to date, suicidal tendencies are only identified by subjective approaches without any biological basis. Campbell aims to reverse this. Campbell Score: Identification and Validation of Objective Biomarker for Suicidal Ideation The Company’s initial goal, to identify molecules associated with propensity towards suicide, was accomplished through the successful completion of phase 1/2 clinical trials demonstrating correlation between its patent-pending biomarker and suicide attempts 1 . The diagnostic test, termed the “Campbell Score” utilizes proprietary technology to accurately quantify an immunological cytokine which historically has been shown to be associated with brain inflammation. However, it has not been practically utilized as a marker of suicidality until now. Having proven the viability of this marker, the Company is currently focusing on accelerating development of a saliva-based method of assessment, which will provide in-office, real-time results. Rationale for testing of inflammatory markers as a means of quantifying suicidal tendencies was described in a paper published by the Company 2 . Publication and Issuance of Patents on Intervening in Suicide-Prone/Addiction/Depression In order to provide therapeutic approaches for preventing suicide, based on reducing brain inflammation and stimulating neural regeneration, the Company has licensed and developed numerous therapeutic products. Intellectual property to both the diagnostic test and interventions has been exclusively licensed from Therapeutic Solutions International. Some of the exciting patents that have been published/issued are listed below: 1. Immunotherapy for Opioid Addiction 3 . This 700-claim published patent application provides means of using oxytocin and various biologics as novel treatments for opioid addiction through stimulation of neural regeneration combined with anti-inflammatory effects. Campbell is planning to partner/license with various organizations to accelerate development and/or augment existing therapeutic approaches. 2. Treatment of Major Depressive Disorder and Suicidal Ideations Through Stimulation of Hippocampal Neurogenesis Utilizing Plant-Based Approaches 4 . Various compositions of matter are disclosed which reduce depressive symptoms using non-SSRI approaches. Some of the disclosed treatment compositions include combinations of minocycline with human chorionic gonadotrophin, as well as mixtures of various inhibitors of the inflammatory pathway NF-kappa B. The compositions disclosed can be utilized as monotherapies or can be incorporated into existing conventional psychotherapy protocols. The patent application also provides means of quantifying efficacy of the intervention before clinical effects are observed. 3. Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention 5 . Protocols are disclosed for generation of unique patient-specific therapeutics to reduce some of the pathological pathways associated with propensity towards self-harm. This patent is based in part on some of the findings discovered in the Campbell Score trial. 4. Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline 6 . Means of increasing levels of immune cells which possess ability to reduce brain inflammation and indirectly stimulate regeneration of damaged brain tissue are disclosed. 5. Neuroprotection and Neurodegeneration by Pterostilbene and Compositions Thereof 7 . The ability to utilize various natural compounds alone or in combination for stimulation of brain inflammation suppressing mechanisms are disclosed in this issued patent. 6. Treatment of Major Depressive Disorder by Low Dose Interleukin-2 8 . Interleukin-2 is an FDA approved immune modulating drug that has conventionally been used in treatment of cancer. Disclosed are means of using lower concentrations of this drug to induce specific immune alterations that possess therapeutic activities in major depressive disorder and other mental conditions. 7. Therapeutic Monocytes for Prevention of Suicidal Ideation 9 . Monocytes are manipulated in vitro and/or in vivo to endow specific phenotypes that induce immunological processes typically associated with remission from mental disease and/or suicidal ideations. Expansion of Internationally Renowned Advisory Board The Company has assembled an advisory board comprising of Dr. Peter Farrell 10 , Benjamin Floyd, Howard Leonhard, Dr. Pablo Guzman, J Christopher Mizer, Darren Maggot and Justin Parsons. The latest addition was Dr. Bradley Messmer (CEO of NASDAQ public company Aegirbio (AEGIR) who has successfully developed several diagnostic devices. Closing First PPM and Increased Valuation The Company closed its private placement memorandum at 25 cents a share in August 2022 which funded the mentioned progress. The Company has launched a new PPM at $1.00 a share in January of this year. The protein marker that we identified has subsequently been accepted by the scientific community as playing a role in the neuroinflammatory processes associated with tendency for self-harm and other mental health issues. Based on advice from our advisory board, the Company made the decision to focus on leveraging existing data into development of a saliva-based test identifying the same protein marker. This decision was made in part because the majority of end users (psychiatrists) do not have readily available access to blood draw. Additionally, making it simpler and less traumatic is believed to increase greater compliance. About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com . 1 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction | BioSpace 2 Suicide: An Immunological Disorder? by Kalina O'Connor :: SSRN 3 US Patent Application for IMMUNOTHERAPY FOR OPIOID ADDICTION Patent Application (Application #20220193127 issued June 23, 2022) - Justia Patents Search 4 US20220175701 TREATMENT OF MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATIONS THROUGH STIMULATION OF HIPPOCAMPAL NEUROGENESIS UTILIZING PLANT-BASED APPROACHES (wipo.int) 5 US Patent Application for Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention Patent Application (Application #20220088086 issued March 24, 2022) - Justia Patents Search 6 US Patent Application for Upregulation of Therapeutic T Regulatory Cells and Suppression of Suicidal Ideations in Response to Inflammation by Administration of Nutraceutical Compositions Alone or Combined with Minocycline Patent Application (Application #20220062367) 7 11504410 (uspto.gov) 8 US Patent Application for TREATMENT OF MAJOR DEPRESSIVE DISORDER BY LOW DOSE INTERLEUKIN-2 Patent Application (Application #20220362341 issued November 17, 2022) - Justia Patents Search 9 20220280574 (uspto.gov) 10 Therapeutic Solutions International Announces Titan of Industry Dr. Peter Farrell Joins Advisory Board of its Suicide Prevention Spin-Off Campbell Neurosciences (prnewswire.com)

ImmunotherapyClinical Study

09 Nov 2022

·www.prnewswire.com

Human Chorionic Gonadotropin (hCG) Market to grow by USD 303.49 Mn; Driven by an increase in the prevalence of infertility - Technavio

NEW YORK, Nov. 9, 2022 /PRNewswire/ -- The " Human Chorionic Gonadotropin (HCG) Market by Technology and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The report expects the market size to grow by USD 303.49 million, accelerating at a CAGR of 6.7% during the forecast period. The report provides a detailed analysis of the factors influencing growth, vendor landscape, the latest trends, major revenue-generating segments, and regional growth opportunities. Understand the scope of the full report by Downloading Free PDF Sample Report. Market Dynamics: Continue Reading Technavio has announced its latest market research report titled Global Human Chorionic Gonadotropin (hCG) Market 2022-2026 The increasing infertility rate is one of the major reasons that drive the hCG market growth. According to a recent study, about 7% of married women aged 15-44 years in the US cannot get pregnant after a year of trying to conceive. Also, about 12% of women aged 15-44 years in the US have difficulty carrying a pregnancy to term, which is termed impaired fecundity. Most couples struggle with infertility and seek medical help for conception or pregnancy problems. In women, hCG improves ovulatory and final follicle maturation and offers luteal phase assistance during infertility treatment. This is expected to increase the demand for infertility treatment, which in turn, will drive the market growth during the forecast period. Get highlights into the impact of drivers, trends, and challenges on the growth of the global roti maker market. Download Free Sample Report Segmentation Analysis: Human Chorionic Gonadotropin (hCG) Market Technology Outlook (Revenue, USD Million, 2021-2026) Natural source extraction - size and forecast 2021-2026 Recombinant technology - size and forecast 2021-2026 The market growth will be significant in the natural source extraction segment over the forecast period. The rising prevalence of hypogonadism-related illnesses in men, particularly in older adults, is a primary growth factor in the segment. The segment will also be driven by the increased accessibility of infertility treatment and services, along with increasing infertility issues. Human Chorionic Gonadotropin (hCG) Market Geography Outlook (Revenue, USD Million, 2021-2026) North America - size and forecast 2021-2026 Europe - size and forecast 2021-2026 Asia - size and forecast 2021-2026 Rest of World (ROW) - size and forecast 2021-2026 North America will account for 37% of the global market share over the forecast period. The increase in the incidences of infertility and the growing awareness of infertility treatments are likely to fuel the growth of the market in North America. Also, changes in reimbursement policies on infertility treatments, medical tourism, and the rising number of vendors in the region will contribute to the growth of the regional market. Identify potential segments to invest in over the forecast period. Buy Report Now! Start for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Major Vendors in Human Chorionic Gonadotropin (hCG) Market: Biocare Medical LLC Cigna Corp. Cipla Ltd. Ferring B.V. Fresenius Kabi AG Intas Pharmaceuticals Ltd. Kamia Biomedical Company Lee BioSolutions Inc Lupin Ltd. Merck and Co. Inc. MyBioSource Inc. Prospec Tany Technogene Ltd. Sanzyme P Ltd. Scripps Laboratories Inc. Sun Pharmaceutical Industries Ltd. Technavio's sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report Related Reports: The peptide therapeutics market share is expected to increase to USD 23.36 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 12.52%. The increasing prevalence of infectious diseases is notably driving the peptide therapeutics market growth, although factors such as complexities in manufacturing, storage conditions, distribution policies, and high cost may impede market growth. The multiple myeloma drugs market size is expected to increase by USD 6419.94 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.9%. The growing incidence of multiple myeloma is notably driving the multiple myeloma drugs market growth, although factors such as the growing popularity of complementary and alternative medicine may impede the market growth. Table of contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Technology Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Technology 5.1 Market segments Exhibit 24: Chart on Technology - Market share 2021-2026 (%) Exhibit 25: Data Table on Technology - Market share 2021-2026 (%) 5.2 Comparison by Technology Exhibit 26: Chart on Comparison by Technology Exhibit 27: Data Table on Comparison by Technology 5.3 Natural source extraction - Market size and forecast 2021-2026 Exhibit 28: Chart on Natural source extraction - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Natural source extraction - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Natural source extraction - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Natural source extraction - Year-over-year growth 2021-2026 (%) 5.4 Recombinant technology - Market size and forecast 2021-2026 Exhibit 32: Chart on Recombinant technology - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Recombinant technology - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Recombinant technology - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Recombinant technology - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Technology Exhibit 36: Market opportunity by Technology ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 China - Market size and forecast 2021-2026 Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 Canada - Market size and forecast 2021-2026 Exhibit 74: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 Cigna Corp. Exhibit 85: Cigna Corp. - Overview Exhibit 86: Cigna Corp. - Product / Service Exhibit 87: Cigna Corp. - Key offerings 10.4 Ferring B.V. Exhibit 88: Ferring B.V. - Overview Exhibit 89: Ferring B.V. - Product / Service Exhibit 90: Ferring B.V. - Key offerings 10.5 Fresenius Kabi AG Exhibit 91: Fresenius Kabi AG - Overview Exhibit 92: Fresenius Kabi AG - Business segments Exhibit 93: Fresenius Kabi AG - Key news Exhibit 94: Fresenius Kabi AG - Key offerings Exhibit 95: Fresenius Kabi AG - Segment focus 10.6 Intas Pharmaceuticals Ltd. Exhibit 96: Intas Pharmaceuticals Ltd. - Overview Exhibit 97: Intas Pharmaceuticals Ltd. - Product / Service Exhibit 98: Intas Pharmaceuticals Ltd. - Key offerings 10.7 Lee BioSolutions Inc Exhibit 99: Lee BioSolutions Inc - Overview Exhibit 100: Lee BioSolutions Inc - Product / Service Exhibit 101: Lee BioSolutions Inc - Key offerings 10.8 Lupin Ltd. Exhibit 102: Lupin Ltd. - Overview Exhibit 103: Lupin Ltd. - Product / Service Exhibit 104: Lupin Ltd. - Key news Exhibit 105: Lupin Ltd. - Key offerings 10.9 Merck and Co. Inc. Exhibit 106: Merck and Co. Inc. - Overview Exhibit 107: Merck and Co. Inc. - Business segments Exhibit 108: Merck and Co. Inc. - Key news Exhibit 109: Merck and Co. Inc. - Key offerings Exhibit 110: Merck and Co. Inc. - Segment focus 10.10 Sanzyme P Ltd. Exhibit 111: Sanzyme P Ltd. - Overview Exhibit 112: Sanzyme P Ltd. - Product / Service Exhibit 113: Sanzyme P Ltd. - Key offerings 10.11 Scripps Laboratories Inc. Exhibit 114: Scripps Laboratories Inc. - Overview Exhibit 115: Scripps Laboratories Inc. - Product / Service Exhibit 116: Scripps Laboratories Inc. - Key offerings 10.12 Sun Pharmaceutical Industries Ltd. Exhibit 117: Sun Pharmaceutical Industries Ltd. - Overview Exhibit 118: Sun Pharmaceutical Industries Ltd. - Product / Service Exhibit 119: Sun Pharmaceutical Industries Ltd. - Key offerings 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 120: Inclusions checklist Exhibit 121: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 122: Currency conversion rates for US$ 11.4 Research methodology Exhibit 123: Research methodology Exhibit 124: Validation techniques employed for market sizing Exhibit 125: Information sources 11.5 List of abbreviations Exhibit 126: List of abbreviations About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

100 Deals associated with Human Chorionic Gonadotrophin (Mochida Pharmaceutical Co., Ltd.)

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Abortion, Habitual	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Abortion, Threatened	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Anovulation	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Cryptorchidism	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Delayed Puberty	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Hypogonadism	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Infertility, Male	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Metrorrhagia	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973
Pituitary Diseases	Japan	Mochida Pharmaceutical Co., Ltd.	20 Jan 1973

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECTRIMS2019	Not Applicable	Multiple Sclerosis Human chorionic gonadotrophin (hCG)	-	urinary hCG	sguwifpjpm(gquluyghac) = ylxfuslycc flxpfobsvj (castxnpkhm ) View more	Positive	10 Sep 2019
				recombinant hCG	sguwifpjpm(gquluyghac) = fjavbfihha flxpfobsvj (castxnpkhm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis